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Introduction {#sec005}
============

Candida esophagitis (CE), one of the most common opportunistic infections of the esophagus \[[@pone.0133589.ref001]\], is classed as an invasive fungal disease \[[@pone.0133589.ref002]\]. Severe CE may cause esophageal hemorrhage or progress to stricture or fistula formation, accompanied by reduced quality of life. Early diagnosis and treatment with systemic antifungals is therefore important \[[@pone.0133589.ref003]\]. Endoscopy is an essential diagnostic tool for detecting fungal white plaque and performing biopsy \[[@pone.0133589.ref004]\], but it is too costly and invasive to be used in an unselected population. Therefore, high-risk patients must be identified to prevent delays in diagnosis and poor outcomes.

Several studies have reported that proton-pump inhibitors (PPIs), immunosuppressants, and HIV infection are common risk factors for CE, although most of these studies did not have a case-control design, had a small samples, or were restricted to immunocompromised patients \[[@pone.0133589.ref005]--[@pone.0133589.ref008]\]. In today's rapidly aging society, it is unclear whether these risk factors remain the same given that comorbidities in general are expected to rise with rapid aging of the population \[[@pone.0133589.ref009]\] and the suggested risk factors of PPIs and immunosuppressant drugs \[[@pone.0133589.ref006],[@pone.0133589.ref008],[@pone.0133589.ref010]\] are now in widespread clinical use. In contrast, it is known that HIV-related opportunistic infections have decreased dramatically following the introduction of highly active antiretroviral therapy (HAART) \[[@pone.0133589.ref011],[@pone.0133589.ref012]\]. Moreover, few studies have investigated CE risk factors in the recent decade and long-term trends in CE prevalence have not been studied to date \[[@pone.0133589.ref007],[@pone.0133589.ref010]\]. In light of such societal changes, the risk factors for CE should be reconsidered and trends in CE prevalence investigated to facilitate timely diagnosis and treatment of the disease.

Here we report the results of a large, endoscopy-based, cross-sectional, case-control study conducted over 13 years that aimed to identify trends in annual CE prevalence in patients with or without HIV infection and determine through risk analysis which lifestyle factors, medication, and comorbidities are associated with CE.

Materials and Methods {#sec006}
=====================

Study design, setting, and participants {#sec007}
---------------------------------------

We conducted two studies at the endoscopy unit of the National Center for Global Health and Medicine (NCGM; Tokyo, Japan) between January 2002 and April 2014, one to investigate CE prevalence and the other to examine risk factors for CE. This study was approved by the ethics committee of the National Center for Global Health and Medicine Center (Nos. 711, 1424) and was implemented in accordance with the provisions of the Declaration of Helsinki. NCGM has 900 beds and is the largest referral center for HIV/AIDS in Japan. All patients underwent serological testing for HIV, hepatitis B virus (HBV), hepatitis C virus (HCV), and syphilis before endoscopy \[[@pone.0133589.ref013]\]. Written informed consent was obtained from all patients prior to endoscopy.

In Study 1 to identify overall CE prevalence and trends in annual CE prevalence, we reviewed a hospital-based, prospectively collected endoscopic database of 80,360 consecutive patients who underwent upper endoscopy at NCGM between January 2002 and April 2014. Indications for endoscopy were as follows: (i) continual or intermittent upper GI symptoms; (ii) asymptomatic with anemia; (iii) asymptomatic requiring examination for specific diseases due to abnormal findings on tumor marker or fecal occult blood testing or on abdominal imaging; (iv) screening required for gastric cancer; and (v) therapeutic endoscopy required. In Japan, which has a high incidence of gastric cancer \[[@pone.0133589.ref014]\], endoscopy is frequently performed for gastric cancer screening \[[@pone.0133589.ref015]\]. We excluded patients who were ≤18 years of age or who did not provide informed consent. All inclusion and exclusion criteria were fullfilled before the patients were enrolled.

In Study 2 to identify CE risk factors, we conducted a hospital-based, case-control study at the endoscopy unit of the NCGM between September 2009 and April 2014. Inclusion criteria were Japanese nationality and the aforementioned indications for endoscopy. Exclusion criteria were as follows: (i) no informed consent obtained; (ii) unknown use of medication; (iii) not independent in activities of daily living (ADL); (iv) inability to understand written documents; (v) use of any anti-fungal drugs within 1 month before endoscopy; (vi) urgent or early endoscopy for acute GI bleeding; and (vii) second endoscopy required during the study period. All inclusion and exclusion criteria were fullfilled before the patients were enrolled. The control group comprised 5,800 patients undergoing endoscopy during the same period who did not meet our criteria for the diagnosis of CE.

Data sources and measurement {#sec008}
----------------------------

For risk analysis, histories of HBV, HCV, and syphilis infection were collected before endoscopy and defined as presence of antibody against hepatitis B or C surface antigen and positive results on a *Treponema pallidum* hemagglutination test, respectively, as previously reported \[[@pone.0133589.ref013]\].

A detailed questionnaire was also completed at the endoscopy unit on the same day as before endoscopy \[[@pone.0133589.ref016]\]. Well-trained medical researchers asked patients about alcohol consumption, smoking status, comorbidities, and medication use. Researchers also checked prescriptions and medical records in addition to the information provided by the patients to avoid omissions. Alcohol consumption was defined as consumption of alcohol at least once a week. Smoking was defined as currently smokes or ever smoked. Comorbidities included diabetes mellitus (DM), cardiovascular disease, cerebrovascular disease, chronic kidney disease (CKD), liver cirrhosis, peptic ulcer disease, post-esophageal resection, and post-gastric resection. DM was considered present in patients taking anti-diabetes drugs. CKD was considered present in patients on hemodialysis or peritoneal dialysis, or with serum creatinine levels ≥2.0 mg/dl. Patients were asked to indicate which drugs, if any, they had used based on drugs pictured in the questionnaire, as previously reported \[[@pone.0133589.ref017],[@pone.0133589.ref018]\]. Use of a drug was defined as intermittent or regular administration within 1 month before the questionnaire interview. Patients were asked about the following medication use: anticancer drugs for solid or hematological tumors; 5 types of systemic corticosteroids (prednisone, methylprednisolone, betamethasone, dexamethasone, and hydrocortisone) and daily corticosteroid dose; 8 types of non-steroidal anti-inflammatory drugs (NSAIDs); acetaminophen; 4 types of PPIs (lansoprazole, rabeprazole, omeprazole, and esomeprazole); and 6 types of H2RAs (nizatidine, roxatidine, famotidine, ranitidine, lafutidine, and cimetidine). We calculated prednisone-equivalent daily corticosteroid dose based on the data that glucocorticoid doses providing anti-inflammatory effects approximately equivalent to 5 mg prednisone are methylprednisolone 4 mg, betamethasone 0.75 mg, dexamethasone 0.75mg, and hydrocortisone 20 mg \[[@pone.0133589.ref019]\].

For HIV-infected patients, routes of infection were determined using questionnaires administered by medical staff \[[@pone.0133589.ref020]\] and classified into one of six categories: homosexual, bisexual, heterosexual, drug user, use of untreated blood products, or unknown. Sexual behavior was divided into two categories: men who have sex with men (MSM) and heterosexual. Patients who were neither homosexual nor bisexual were regarded as heterosexual. CD4 cell count values obtained within 1 month before or after endoscopy were obtained from the medical records.

Diagnosis of upper GI disease and candida esophagitis {#sec009}
-----------------------------------------------------

A high-resolution scope (GIF-H260, Olympus Corp., Tokyo, Japan) was used for diagnosis of upper GI diseases. Well-trained staff performed endoscopy while blinded to the questionnaire results. When abnormal findings were detected on endoscopy, biopsy or endoscopic mucosal resection was performed. All removed specimens were evaluated by expert pathologists (\>10 years of experience), and final diagnoses of upper GI diseases were made. Diagnosis of CE was made on the basis that candida white plaques in the esophagus, detected by endoscopy, cannot be washed away \[[@pone.0133589.ref021]\] ([Fig 1A and 1B](#pone.0133589.g001){ref-type="fig"}) and confirmation by pathological assessment with hematoxylin and eosin and periodic acid-Schiff staining ([Fig 1C](#pone.0133589.g001){ref-type="fig"}) or culture for *Candida* species \[[@pone.0133589.ref017],[@pone.0133589.ref018]\].

![Endoscopic findings (A, B) and pathological findings (C) of candida esophagitis.\
(A) Confluent, linear, and nodular elevated plaques. (B) Thick white plaque cover on esophageal mucosa circumferential narrowing the lumen. (C). Numerous Candida pseudohyphae and spores in the exfoliated esophageal epithelium and detached superficial squamous epithelium (×400).](pone.0133589.g001){#pone.0133589.g001}

Statistical analysis {#sec010}
--------------------

In Study 1, we examined trends in CE prevalence over the 13-year study period in all subjects, HIV-infected patients, and non-HIV-infected patients, assessing changes in prevalence in 2-year bins with the Chi-squared test for linear trends.

In Study 2, we summarized descriptive data for patients with and without CE to identify risk factors. Patient characteristics were compared using the Mann-Whitney U test for quantitative variables or the Chi-square test or Fisher's exact test for qualitative variables. The association between CE and other upper GI diseases was evaluated from both the endoscopy and pathology findings. CE risk factors were identified using a multiple logistic regression model including factors with a significance of P\<0.2 on univariate analysis. Odds ratios and 95% confidence intervals were calculated. CE risk factors were also evaluated separately for HIV-infected and non-HIV-infected patients.

A *P* value of less than 0.05 was considered statistically significant. All statistical analyses were performed using Stata version13 software (StataCorp, College Station, TX).

Results {#sec011}
=======

Study 1: Trends in CE Prevalence {#sec012}
--------------------------------

Between January 2002 and April 2014, 80,360 patients underwent upper endoscopy at NCGM. After exclusion, 80,219 patients were left for analysis. CE prevalence was 1.7% (1,375/80,219) in all patients, 9.8% (156/1,595) in HIV-infected patients, 1.6% (1,219/78,624) in non-HIV-infected patients, and 1.8% (785/42,555) in patients aged \>65 years. CE prevalence from 2002--2003 to 2012--2014 tended to increase in all subjects (0.8% to 2.7%, P\<0.01 by trend test) ([Fig 2A](#pone.0133589.g002){ref-type="fig"}) and in non-HIV-infected patients (0.6% to 2.5%, P\<0.01 by trend test) ([Fig 2B](#pone.0133589.g002){ref-type="fig"}), but decrease in HIV-infected patients (13.6% to 9.0%, P = 0.097 by trend test) ([Fig 2C](#pone.0133589.g002){ref-type="fig"}).

![Trends in prevalence of candida esophagitis, 2002--2014.\
(A) All subjects, (B) non-HIV-infected patients, (C) HIV-infected patients. Values on bars are number of subjects testing positive/total number tested. Error bars show 95% confidential intervals.](pone.0133589.g002){#pone.0133589.g002}

Study 2: Risk factors for CE {#sec013}
----------------------------

### Patient characteristics {#sec014}

Between September 2009 and April 2014, among the 32,827 patients who underwent upper endoscopy, we did not conduct questionnaire interviews with 23,485 patients because they either did not provide informed consent, did not know what medications they were receiving, were not independent in ADL, or could not understand written documents, and we found 3,331 patients met one of the exclusion criteria. This left a subcohort of 6,011 patients who underwent endoscopy and completed the questionnaire interview for analysis of CE risk.

Baseline characteristics are shown in [Table 1](#pone.0133589.t001){ref-type="table"}. The factors significantly associated with CE were alcohol consumption, HIV infection, CD4 cell count, history of HAART, HCV infection, syphilis, and use of corticosteroids, NSAIDs, acetaminophen, or PPIs. As shown in [Table 2](#pone.0133589.t002){ref-type="table"}, the upper GI diseases significantly associated with CE were esophageal ulcer, gastric ulcer, and severe atrophic gastritis.

10.1371/journal.pone.0133589.t001

###### Patient characteristics in the entire cohort and groups with or without candida esophagitis.

![](pone.0133589.t001){#pone.0133589.t001g}

                                           All (n = 6,011)   CE (n = 211)    Non-CE (n = 5,800)   P[\*](#t001fn003){ref-type="table-fn"}
  ---------------------------------------- ----------------- --------------- -------------------- ----------------------------------------
  Age, years                               59.6±14.2         60.3±15.0       59.6±14.2            0.469
  Sex, male                                3,397 (56.5)      128 (60.7)      3,269 (56.4)         0.216
  Alcohol                                  3,185 (3.0)       97 (46.0)       3,088 (53.2)         0.038
  Smoker                                   2,758 (45.9)      110 (52.1)      2,648 (45.7)         0.064
  Infection                                                                                       
  HIV infection                            430 (7.2)         48 (22.8)       382 (7.6)            \<0.001
  Infectious route                                                                                
   Homosexual                              255 (59.3)        30 (62.5)       225(58.9)            0.632
   Bisexual                                41 (9.5)          7 (14.6)        34 (8.9)             0.206
   Heterosexual                            67 (15.6)         6 (12.5)        61 (16.0)            0.532
   Drug user                               2 (0.5)           0 (0)           2 (0.5)              0.615
   Untreated blood products                46 (10.7)         2 (4.2)         44 (11.5)            0.120
   unknown                                 19 (4.4)          3 (6.3)         16 (4.2)             0.512
  CD4 cell count/μL, median (IQR)          405 (222, 584)    143 (30, 403)   432 (262, 597)       \<0.001
  CD4 cell count/ \<100/μL                 65 (15.1)         23 (47.9)       42 (11.0)            \<0.001
  History of HAART                         342 (79.5)        24 (50.0)       318 (83.3)           \<0.001
  Duration of HAART (months)               76.4±60.9         68.0±71.6       77.1±60.0            0.212
  HBV infection                            130 (2.2)         3 (1.4)         127 (2.2)            0.451
  HCV infection                            339 (5.6)         20 (9.5)        319 (5.5)            0.014
  Syphilis                                 172 (2.9)         18 (8.5)        154 (2.7)            \<0.001
  Comorbidities                                                                                   
  Diabetes mellitus                        783 (13.0)        25 (11.9)       758 (13.1)           0.605
  Cardiovascular disease                   444 (7.4)         16 (7.6)        428 (7.4)            0.912
  Cerebrovascular disease                  28 (0.5)          1 (0.5)         27 (0.5)             0.986
  Chronic kidney disease                   191 (3.2)         5 (2.4)         186 (3.2)            0.496
  Liver cirrhosis                          587 (9.8)         24 (11.4)       563 (9.7)            0.423
  Peptic ulcer disease                     1,577 (26.2)      58 (27.5)       1,519 (26.2)         0.674
  Post-esophageal resection                27 (0.5)          2 (1.0)         25 (0.4)             0.270
  Post-gastric resection                   270 (4.5)         5 (2.4)         265 (4.6)            0.130
  Drugs                                                                                           
  Anticancer drugs                         43 (0.7)          2 (1.0)         41 (0.7)             0.683
  Corticosteroids                          404 (6.7)         56 (26.5)       348 (6.0)            \<0.001
   Prednisone                              359 (6.0)         50 (23.7)       309 (5.3)            \<0.001
   Methylprednisolone                      16 (0.3)          2 (1.0)         14 (0.2)             0.050
   Betamethasone                           9 (0.2)           1 (0.5)         8 (0.1)              0.215
   Dexamethasone                           10 (0.2)          1 (0.5)         9 (0.2)              0.264
   Hydrocortisone                          10 (0.2)          2 (1.0)         8 (0.1)              0.005
   Prednisone-equivalent daily dose (mg)   10.7±18.6         15.5±20.5       9.94±18.2            0.047
  NSAIDs                                   540 (9.0)         27 (12.8)       513 (8.8)            0.049
  Acetaminophen                            156 (2.6)         13 (6.2)        143 (2.5)            0.001
  Proton pump inhibitor                    1,678 (27.9)      76 (36.0)       1,602 (27.6)         0.008
   Lansoprazole                            793 (13.2)        34 (16.1)       759 (13.1)           0.202
   Rabeprazole                             301 (5.0)         12 (5.7)        289 (5.0)            0.645
   Omeprazole                              457 (7.6)         19 (9.0)        438 (7.6)            0.434
   Esomeprazole                            160 (2.7)         10 (4.7)        150 (2.6)            0.056
  H2RA                                     468 (7.8)         21 (10.0)       447 (7.7)            0.232

CE, candida esophagitis; HIV, human immunodeficiency virus; IQR, interquartile range; HAART, highly active anti-retroviral therapy; HBV, hepatitis B virus; HCV, hepatitis C virus; NSAIDs, non-steroidal anti-inflammatory drugs; H2RA, H2-receptor antagonist.

Data are presented as number (%) or mean ±SD.

\**p* values for the comparison between patients with CE and those without CE.

10.1371/journal.pone.0133589.t002

###### Upper gastrointestinal diseases concomitant with candida esophagitis evaluated by endoscopy with pathology.

![](pone.0133589.t002){#pone.0133589.t002g}

  Upper GI disease             All (n = 6,011)   CE (n = 211)   Non-CE (n = 5,800)   P[\*](#t002fn003){ref-type="table-fn"}
  ---------------------------- ----------------- -------------- -------------------- ----------------------------------------
  Reflux esophagitis           651 (10.8)        15 (7.1)       636 (11.0)           0.077
  Esophageal ulcer             33 (0.6)          5 (2.4)        28 (0.5)             \<0.001
  Esophageal advanced cancer   33 (0.6)          1 (0.5)        32 (0.6)             0.881
  Esophageal malignancy        21 (0.4)          0 (0.0)        21 (0.4)             0.381
  Gastric ulcer                271 (4.5)         16 (7.6)       255 (4.4)            0.028
  Atrophic gastritis           3,030 (50.4)      115 (54.5)     2,915 (50.3)         0.226
   Mild to moderate type       2199 (36.6)       70 (33.2)      2129 (36.7)          0.295
   Severe type                 669 (11.4)        38 (18.6)      631 (11.2)           0.001
  Gastric advanced cancer      32 (0.5)          2 (1.0)        30 (0.5)             0.398
  Gastric malignancy           174 (2.9)         9 (4.3)        165 (2.8)            0.227
  Duodenal ulcer               100 (1.7)         5 (2.4)        95 (1.6)             0.414
  Duodenal malignancy          78 (1.3)          4 (1.9)        74 (1.3)             0.434

GI, gastrointestinal; CE, candida esophagitis.

Data are presented as number (%).

\**p* values for the comparison between patients with CE and those with non-CE.

### Univariate and multivariate odds ratios for CE {#sec015}

Risk factors for CE identified by multivariate analysis are shown in [Table 3](#pone.0133589.t003){ref-type="table"}. Increasing age, HIV infection, and corticosteroid use were independently associated with CE and smoker and acetaminophen were marginally associated with CE, but sex, alcohol consumption, HCV infection, syphilis, post-gastric resection, and use of NSAIDs or PPIs were not.

10.1371/journal.pone.0133589.t003

###### Risk factors for candida esophagitis (n = 6,011).

![](pone.0133589.t003){#pone.0133589.t003g}

  Factors                     Crude OR            P         Adjusted OR         P
  --------------------------- ------------------- --------- ------------------- ---------
  Age, years                  1.00 (0.99--1.01)   0.504     1.02 (1.00--1.03)   0.007
  Sex, male                   1.19 (0.90--1.58)   0.216     1.08 (0.76--1.54)   0.651
  Alcohol                     0.75 (0.57--0.98)   0.038     0.87 (0.64--1.17)   0.351
  Smoker                      1.30 (0.98--1.71)   0.064     1.32 (0.96--1.81)   0.085
  HIV infection               4.18 (2.98--5.86)   \<0.001   4.92 (3.11--7.79)   \<0.001
  HBV infection               0.64 (0.20--2.04)   0.451     NA                  NA
  HCV infection               1.80 (1.12--2.89)   0.015     1.40 (0.85--2.31)   0.184
  Syphilis                    3.42 (2.06--5.69)   \<0.001   1.32 (0.73--2.39)   0.356
  Diabetes mellitus           0.89 (0.58--1.36)   0.595     NA                  NA
  Cardiovascular disease      1.03 (0.61--1.73)   0.911     NA                  NA
  Cerebrovascular disease     1.02 (0.14--7.53)   0.986     NA                  NA
  Chronic kidney disease      0.72 (0.30--1.74)   0.760     NA                  NA
  Liver cirrhosis             1.20 (0.77--1.85)   0.419     NA                  NA
  Peptic ulcer disease        1.20 (0.79--1.82)   0.674     NA                  NA
  Post-esophageal resection   2.21 (0.52--9.39)   0.270     NA                  NA
  Post-gastric resection      0.51 (0.21--1.24)   0.137     0.61 (0.25--1.52)   0.291
  Anticancer drugs            1.34 (0.32--5.59)   0.684     NA                  NA
  Corticosteroids             5.66 (4.09--7.83)   \<0.001   5.90 (4.10--8.50)   \<0.001
  NSAIDs                      1.51 (1.00--2.29)   0.050     1.08 (0.69--1.67)   0.745
  Acetaminophen               2.60 (1.45--4.66)   0.001     1.70 (0.91--3.16)   0.097
  Proton pump inhibitor       1.48 (1.11--1.97)   0.008     1.11 (0.80--1.53)   0.532
  H2RA                        1.32 (0.83--2.10)   0.233     NA                  NA

OR, odds ratio; HIV, human immunodeficiency virus; HBV, hepatitis B virus; HCV, hepatitis C virus; NSAIDs, non-steroidal anti-inflammatory drugs; H2RA, H2-receptor antagonists; NA, not applicable.

Values in parentheses represent 95% confidential intervals.

The risk factors identified by multivariate analysis for HIV-infected and non-HIV-infected patients are shown in [Table 4](#pone.0133589.t004){ref-type="table"}. In HIV-infected patients, CD4 cell count\<100μL significantly increased the risk of CE and history of HAART significantly decreased the risk. Among HIV-infected patients, 25% of the CE patients had CD4 cell counts \>400/μL. In non-HIV-infected patients, increasing age and corticosteroid use were independently associated with CE, and HCV infection, peptic ulcer disease, and post-esophageal resection were marginally associated. Among corticosteroid users, higher prednisone-equivalent daily corticosteroid doses significantly increased the risk for CE ([Table 5](#pone.0133589.t005){ref-type="table"}).

10.1371/journal.pone.0133589.t004

###### Risk factors for candida esophagitis between patients with HIV infection (n = 430) and those without HIV infection (n = 5,581).

![](pone.0133589.t004){#pone.0133589.t004g}

  ------------------------------------------- ------------------------------- -------------------- --------- -------------------- ---------
  **HIV-infected patients (n = 430)**                                                                                             
  **Factors**                                 **Case/ Control (48/382)**      **Crude OR**         **P**     **Adjusted OR**      **P**
  Age, years                                  46.0 ± 12.1 / 46.8 ± 11.6       0.99 (0.97--1.02)    0.678     1.02 (0.99--1.05)    0.138
  Sex, male                                   47 / 362                        2.60 (0.34--19.80)   0.357     2.89 (0.29--29.1)    0.369
  Alcohol                                     24 / 212                        0.80 (0.44--1.46)    0.471     NA                   NA
  Smoker                                      31 / 231                        1.19 (0.64--2.23)    0.582     NA                   NA
  HBV infection                               2 / 29                          0.52 (0.12--2.29)    0.387     NA                   NA
  HCV infection                               7 / 60                          0.92 (0.39--2.14)    0.840     NA                   NA
  Syphilis                                    14 / 100                        1.16 (0.60--2.23)    0.659     NA                   NA
  Diabetes mellitus                           3 / 33                          0.72 (0.21--2.45)    0.600     NA                   NA
  Cardiovascular disease                      2 /11                           1.49 (0.32--6.94)    0.609     NA                   NA
  Cerebrovascular disease                     0 / 1                           NA                   NA        NA                   NA
  Chronic kidney disease                      0 / 13                          NA                   NA        NA                   NA
  Liver cirrhosis                             13 / 114                        0.89 (0.45--1.75)    0.732     NA                   NA
  Peptic ulcer disease                        3 / 64                          0.33 (0.10--1.10)    0.059     0.36 (0.10--1.31)    0.120
  Post-esophageal resection                   0 / 0                           NA                   NA        NA                   NA
  Post-gastric resection                      1 / 3                           2.69 (0.27--26.4)    0.396     NA                   NA
  Anticancer drugs                            1 / 5                           1.60 (0.18--14.03)   0.669     NA                   NA
  Corticosteroids                             10 / 17                         5.65 (2.42--13.21)   \<0.001   2.47 (0.79--7.76)    0.121
  NSAIDs                                      7 / 46                          1.25 (0.53--2.94)    0.614     NA                   NA
  Acetaminophen                               4 / 22                          1.49 (0.49--4.52)    0.483     NA                   NA
  Proton pump inhibitor                       5 / 49                          0.79 (0.30--2.09)    0.635     NA                   NA
  H2RA                                        6 / 16                          3.27 (1.21--8.80)    0.019     2.61 (0.83--8.25)    0.102
  MSM                                         37 / 259                        1.60 (0.79--3.24)    0.194     1.25 (0.57--2.75)    0.581
  CD4 cell count \<100/μL                     23 / 42                         7.45 (3.89--14.28)   \<0.001   4.83 (2.23--10.43)   \<0.001
  History of HAART                            24 / 318                        0.19 (0.10--0.35)    \<0.001   0.35 (0.17--0.74)    0.006
  **Non-HIV-infected patients (n = 5,581)**                                                                                       
  **Factors**                                 **Case/ Control (163/5,418)**   **Crude OR**         **P**     **Adjusted OR**      **P**
  Age, years                                  64.5 ± 13.1 / 60.5 ± 13.9       1.02 (1.01--1.04)    \<0.001   1.02 (1.01--1.03)    0.008
  Sex, male                                   81 / 2,907                      0.85 (0.62--1.17)    0.318     1.01 (0.79--1.56)    0.557
  Alcohol                                     73 / 2,876                      0.72 (0.52--0.98)    0.037     0.97 (0.69--1.37)    0.852
  Smoker                                      79 / 2,417                      1.17 (0.85--1.59)    0.330     NA                   NA
  HBV infection                               1 / 98                          0.34 (0.05--2.42)    0.255     NA                   NA
  HCV infection                               13 / 259                        1.72 (0.97--3.08)    0.065     1.70 (0.94--3.09)    0.081
  Syphilis                                    4 / 54                          2.50 (0.89--6.98)    0.081     2.33 (0.81--6.73)    0.116
  Diabetes mellitus                           22 / 725                        1.00 (0.63--1.58)    0.997     NA                   NA
  Cardiovascular disease                      14 / 417                        1.12 (0.64--1.96)    0.684     NA                   NA
  Cerebrovascular disease                     1 / 26                          1.28 (0.17--9.49)    0.809     NA                   NA
  Chronic kidney disease                      5 / 173                         0.92 (0.41--2.07)    0.979     NA                   NA
  Liver cirrhosis                             11 / 449                        0.80 (0.43--1.48)    0.477     NA                   NA
  Peptic ulcer disease                        55 / 1,455                      1.39 (1.00--1.93)    0.051     1.38 (0.98--1.94)    0.061
  Post-esophageal resection                   2 / 25                          2.68 (0.63--11.41)   0.165     3.72 (0.85--16.31)   0.082
  Post-gastric resection                      4 / 262                         0.50 (0.18--1.35)    0.168     0.52 (0.19--1.42)    0.199
  Anticancer drugs                            1 / 36                          0.92 (0.13--6.77)    0.937     NA                   NA
  Corticosteroids                             49 / 363                        5.99 (4.21--8.51)    \<0.001   5.80 (3.90--8.63)    \<0.001
  NSAIDs                                      20 / 467                        1.48 (0.92--2.39)    0.106     1.06 (0.64--1.77)    0.816
  Acetaminophen                               9 / 121                         2.56 (1.28--5.13)    0.008     1.85 (0.88--3.87)    0.104
  Proton pump inhibitor                       71 / 1,553                      1.92 (1.40--2.63)    \<0.001   1.16 (0.82--1.65)    0.388
  H2RA                                        15 / 431                        1.17 (0.68--2.01)    0.563     NA                   NA
  ------------------------------------------- ------------------------------- -------------------- --------- -------------------- ---------

OR, odds ratio; HIV, human immunodeficiency virus; HBV, hepatitis B virus; HCV, hepatitis C virus; NSAIDs, non-steroidal anti-inflammatory drugs; H2RA, H2-receptor antagonists; MSM, men who have sex with men; HAART, highly active anti-retroviral therapy; NA, not applicable.

Values are number or mean ±SD. Values in parentheses are 95% confidential intervals.

10.1371/journal.pone.0133589.t005

###### Effect of prednisone-equivalent daily corticosteroid dose on risk for candida esophagitis in steroid users (n = 402[\*](#t005fn002){ref-type="table-fn"}).

![](pone.0133589.t005){#pone.0133589.t005g}

  Prednisone-equivalent daily dose (mg)   Case/ control   Crude OR            P       P for trend   Age- and sex- adjusted OR   P       P for trend
  --------------------------------------- --------------- ------------------- ------- ------------- --------------------------- ------- -------------
  \<5 (n = 88)                            8/80            Referent                                  Referent                            
  5--9 (n = 160)                          17/143          1.19 (0.49--2.88)   0.701                 1.18 (0.49--2.86)           0.714   
  10--19 (n = 92)                         16/76           2.11 (0.85--5.20)   0.107                 2.06 (0.82--5.14)           0.122   
  ≥20 (n = 62)                            15/47           3.19 (1.26--8.09)   0.015   0.028         3.09 (1.20--7.97)           0.019   0.043

OR, odds ratio.

\*Of 404 corticosteroid users, 2 were eliminated because of insufficient data.

Values in parentheses are 95% confidential intervals.

Discussion {#sec016}
==========

In this study, we identified that, over the 13-year period from 2002 to 2014, CE prevalence showed significant increases in non-HIV-infected patients but decreases in HIV-infected patients. Moreover, risk analysis revealed that increasing age, HIV infection, and corticosteroids use were independently associated with CE, but alcohol, other infections, diabetes, anticancer drugs, and antisecretory drug use were not. Among HIV-infected patients, low CD4 cell count and absence of HAART were independent risk factors for CE. In corticosteroid users, higher prednisone-equivalent daily corticosteroid dose significantly increased CE risk.

CE prevalence in non-HIV-infected patients is reported to 0.3--7.3% \[[@pone.0133589.ref005],[@pone.0133589.ref008],[@pone.0133589.ref010],[@pone.0133589.ref022],[@pone.0133589.ref023]\], which is consistent with our findings of 1.5% in non-HIV-infected patients. Similarly for HIV-infected patients, CE prevalence was reported to be 42.8--51.8% in the pre-HAART era \[[@pone.0133589.ref024],[@pone.0133589.ref025]\] and 8.5--16.7% in the HAART era \[[@pone.0133589.ref017],[@pone.0133589.ref024]\], with which our finding of 9.8% prevalence in HIV-infected patients, most of whom received HAART (80.3%), concurs.

Little information about CE trends has been available to date, and most studies have focused on HIV-infected patients \[[@pone.0133589.ref012],[@pone.0133589.ref024]\]. Declining CE incidence has been reported in this patient population by Mocroft et al \[[@pone.0133589.ref012]\], from 5.7 person-years in 1994 to 0.5 person-years in 2004, and Nkuize et al \[[@pone.0133589.ref024]\], from 42.8% in 1991--1994, 23.5% in 1999--2002, and 16.7% in 2005--2008. Likewise, CE prevalence decreased from 13.6% in 2002--2003 to 9.0% in 2012--2014 in the present study. This is probably due to the introduction of HAART, which helped avoid immunodeficiency, and the development of effective prophylaxis against opportunistic infection \[[@pone.0133589.ref026]\]. In contrast, CE prevalence in non-HIV-infected patients showed a significant increase over the same period, likely because, in a rapidly aging society, more people have comorbidities and take immunosuppressants \[[@pone.0133589.ref027],[@pone.0133589.ref028]\], which can lead to the development of CE.

Several risk factors for CE have been investigated in case-control studies \[[@pone.0133589.ref006]--[@pone.0133589.ref008],[@pone.0133589.ref010]\], although these studies had a small number of CE cases (three studies; n = 56 \[[@pone.0133589.ref006]--[@pone.0133589.ref008]\], one study; n = 163 \[[@pone.0133589.ref010]\]) and retrospective in nature. They identified corticosteroid or PPIs use, heavy drinking, uncontrolled DM, and cancer as CE risk factors. In our larger scale study investigating the very same factors, multivariate analysis similarly identified systemic corticosteroid use but also revealed increasing age and HIV infection as risk factors for CE.

In terms of systemic corticosteroid use, an association was found in non-HIV-infected patients in this study. This could be explained by the suppression of macrophages and polymorphonuclear leucocytes by glucocorticoids, which can in turn lead to the development of CE \[[@pone.0133589.ref029]\]. Moreover, Heidenreich et al \[[@pone.0133589.ref030]\] showed that glucocorticoids principally affect the capacity of monocytes to control extracellular growth of Candida species by inhibiting tumor necrosis factor alpha secretion. We also found that higher prednisone-equivalent dose of corticosteroids was a risk factor for CE. Among the very few studies to date that have investigated the association between opportunistic infection and steroid dose, Yale et al \[[@pone.0133589.ref031]\] demonstrated that \>30 mg of steroid daily was further associated with worsened *Pneumocystis carinii* pneumonia (PCP), compared with \<30 mg daily, and Porges et al \[[@pone.0133589.ref032]\] demonstrated that \>40 mg daily was associated with PCP development among patients with systemic lupus erythematosus. Our study is the first to investigate the association between steroid dose and CE and our findings suggest that patients who receive high-dose steroids have lower cellular immunity, which can lead to CE development.

Increasing age was identified as a risk factor for CE in non-HIV-infected patients in this study. It is possible that, in non-HIV-infected patients, increasing age leads to impaired immunity due to defects in the hematopoietic bone marrow and in peripheral lymphocyte migration, maturation, and function \[[@pone.0133589.ref009]\]. Another reason could be that increasing age causes a decline in cellular immunity of the epithelial layer, which can lead to colonization of *Candida* species \[[@pone.0133589.ref033]\].

HIV infection itself was a risk factor for CE in this study. We suggest that impaired oral immunity plays a role in this. Oral immunity may be affected earlier than immunity in other organs \[[@pone.0133589.ref034]\] and thus facilitate the development of CE early in HIV infection. Indeed, Chih-Ko et al \[[@pone.0133589.ref034]\] demonstrated that salivary function is impaired early in the course of HIV infection. In the present study, the analysis of HIV-infected subjects showed an association between CD4 cell count \<100/μL and CE, although 25% of HIV-infected patients with CE also had a relatively high CD4 count (CD4\>400). Buchacz et al found that the median CD4 cell count in CE-infected patients increased from 43/μL in the pre-HAART era (1994--1997) to 100/μL in the HAART era (2003--2007). These findings suggest that in the HAART era, HIV-infected patients are likely to develop CE even though their CD4 cell count is relatively high.

Previous studies have suggested that PPIs use is associated with CE because PPIs reduce gastric acidity, an important barrier for most microorganisms, and this can result in a number of infections \[[@pone.0133589.ref035]\]; however, the findings of this association are inconsistent. Chocarro et al \[[@pone.0133589.ref006]\] showed that, among 51 CE patients and 102 controls, PPIs use was independently associated with CE. In contrast, in case-control studies by Weerasuriya et al \[[@pone.0133589.ref007]\] and Choi et al \[[@pone.0133589.ref010]\], PPIs use was not associated with CE, consistent with our data. In clinical practice, PPIs are frequently administered when NSAIDs are used for protection from NSAID-induced peptic ulcer disease, but NSAID use was not adjusted for in previous studies that were also small in scale \[[@pone.0133589.ref006],[@pone.0133589.ref007],[@pone.0133589.ref010]\]. Therefore, a large-scale study with adjustment for NSAIDs is required to identify whether PPIs are a risk of CE.

The strengths of this study include its prospective nature, large scale, and evaluation of detailed HIV information, which was obtained by performing HIV testing in all subjects. Its limitations include the following facts. 1) Because sufficient information was not collected on the pre-endoscopy setting, we could not evaluate the potential risk factors of chronic obstructive pulmonary disease and antibiotic or herbal medication use. 2) Selection bias was present because endoscopy could not be performed for critically ill or intubated patients. 3) Endoscopy is not always performed for HIV-infected patients with oral candidiasis or esophageal symptoms who are empirically treated with antifungal therapy. Thus, this study potentially underestimated the number of CE cases. 4) This study has a cross-sectional design, so we can only comment on risk factors as being associated with disease but we cannot truly understand the causal pathways. 5) This case-control study is potentially affected by recall or interviewer bias, particularly for survey items on alcohol consumption, medication use, and smoking. Therefore, we attempted to limit bias by blinding survey results and performing surveys prior to endoscopy. 6) The community setting of the controls (undergoing endoscopy without CE) may have been different from that of cases (patients with CE); thus, unmeasured confounders exist. In particular, co-morbidities have a confounding effect. In addition, the study would have been better if subjects had been matched for age, sex, and co-morbidities rather than just adjusting the model for these factors.

In conclusion, this study identified that CE prevalence over a 13-year period increased in non-HIV-infected patients but decreased in HIV-infected patients. Besides increasing age, HIV infection itself and corticosteroid use increased the risk for CE development, but antisecretory drug use did not. In HIV-infected patients, a low CD4 count and absence of HAART were independent risk factors for CE. In corticosteroid users, CE was associated with higher prednisone-equivalent dose. Given that the elderly tend to have co-morbidities and take drugs, CE prevalence is expected to continue increasing in today's rapid aging society.
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